{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:35:24Z","timestamp":1790238924540,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T00:00:00Z","timestamp":1497052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ekir.2017.06.004","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T06:46:20Z","timestamp":1497595580000},"page":"1066-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker"],"prefix":"10.1016","volume":"2","author":[{"given":"Claudia","family":"Pontillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.","family":"Schanstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Z\u00fcrbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Ram\u00edrez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lindhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf W.","family":"Bilous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Charturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Vlahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet","family":"Glorieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Delles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.06.004_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2012.64","article-title":"Chapter 1: Definition and classification of CKD","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2017.06.004_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","article-title":"Evolving importance of kidney disease: from subspecialty to global health burden","volume":"382","author":"Eckardt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.06.004_bib3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0140-6736(12)61719-X","article-title":"Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Wang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.06.004_bib4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2017.06.004_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.ajkd.2011.06.006","article-title":"Trial quality in nephrology: how are we measuring up?","volume":"58","author":"Palmer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.06.004_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib8","series-title":"Guideline on the clinical investigation of medicinal products to prevent development\/slow progression of chronic renal insufficiency","year":"2016"},{"key":"10.1016\/j.ekir.2017.06.004_bib9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2017.06.004_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2014.247","article-title":"Proteomic biomarkers in kidney disease: issues in development and implementation","volume":"11","author":"Mischak","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2017.06.004_bib11","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ekir.2017.06.004_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2015.10.010","article-title":"The role of urinary peptidomics in kidney disease research","volume":"89","author":"Klein","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.06.004_bib13","first-page":"5","article-title":"The long path towards implementation of clinical proteomics: exemplified based on CKD273","volume":"11","author":"Nkuipou-Kenfack","year":"2017","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.ekir.2017.06.004_bib14","doi-asserted-by":"crossref","first-page":"e62837","DOI":"10.1371\/journal.pone.0062837","article-title":"CKD273, a new proteomics classifier assessing CKD and its prognosis","volume":"8","author":"Argil\u00e9s","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2017.06.004_bib15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2014050423","article-title":"Diagnosis and prediction of CKD progression by assessment of urinary peptides","volume":"26","author":"Schanstra","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.06.004_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib17","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/elps.201200708","article-title":"Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications","volume":"34","author":"Stalmach","year":"2013","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ekir.2017.06.004_bib18","first-page":"184","article-title":"Declaration of Helsinki","volume":"227","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2017.06.004_bib19","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.06.004_bib20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sj\u00f8lie","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.06.004_bib21","doi-asserted-by":"crossref","first-page":"e0120995","DOI":"10.1371\/journal.pone.0120995","article-title":"A\u00a0panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes","volume":"10","author":"Pena","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2017.06.004_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdiacomp.2015.08.025","article-title":"Estimating glomerular filtration rate: performance of the CKD-EPI equation over time in patients with type 2 diabetes","volume":"30","author":"Wood","year":"2016","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.ekir.2017.06.004_bib23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/ndt\/gfu234","article-title":"The urinary proteome as correlate and predictor of renal function in a population study","volume":"29","author":"Gu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.06.004_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guidelines for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.06.004_bib26","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.2337\/dc08-s249","article-title":"Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?","volume":"31","author":"Basi","year":"2008","journal-title":"Diabet Care"},{"key":"10.1016\/j.ekir.2017.06.004_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/pr800401m","article-title":"Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease","volume":"8","author":"Jantos-Siwy","year":"2009","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.ekir.2017.06.004_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/prca.200900189","article-title":"Comprehensive human urine standards for comparability and standardization in clinical proteome analysis","volume":"4","author":"Mischak","year":"2010","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.ekir.2017.06.004_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(06)70584-8","article-title":"Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis","volume":"7","author":"Theodorescu","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ekir.2017.06.004_bib30","doi-asserted-by":"crossref","first-page":"e010310","DOI":"10.1136\/bmjopen-2015-010310","article-title":"Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial","volume":"2016","author":"Lindhardt","year":"2016","journal-title":"BN+MJ Open"},{"key":"10.1016\/j.ekir.2017.06.004_bib31","first-page":"285","article-title":"Statistical estimates and transformed beta-variables","volume":"3","author":"Blom","year":"1961","journal-title":"Biom J"},{"key":"10.1016\/j.ekir.2017.06.004_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib33","unstructured":"Shin S. ROC analysis for the evaluation of continuous biomarkers: existing tools and new features in SAS\u00ae 9.2 (paper 210-31). 2009;1-15. Available at: http:\/\/www.lexjansen.com\/pharmasug\/2009\/sp\/SP09.pdf."},{"key":"10.1016\/j.ekir.2017.06.004_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/EDE.0000000000000018","article-title":"Net reclassification indices for evaluating risk-prediction instruments: a critical review","volume":"25","author":"Kerr","year":"2014","journal-title":"Epidemiology"},{"key":"10.1016\/j.ekir.2017.06.004_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dom.12583","article-title":"Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes","volume":"18","author":"Schievink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2017.06.004_bib36","first-page":"421","article-title":"Medical costs associated with type 2 diabetes complications and comorbidities","volume":"19","author":"Li","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ekir.2017.06.004_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000313946","article-title":"Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts","volume":"169","author":"Barnes","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.ekir.2017.06.004_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2613.2011.00764.x","article-title":"Fibroblasts and myofibroblasts in renal fibrosis","volume":"92","author":"Meran","year":"2011","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ekir.2017.06.004_bib39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ndt\/17.6.1005","article-title":"Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease","volume":"17","author":"H\u00f6rstrup","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.06.004_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2008.10.003","article-title":"Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring","volume":"28","author":"Fisher","year":"2009","journal-title":"Matrix Biol"},{"key":"10.1016\/j.ekir.2017.06.004_bib41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ki.2011.214","article-title":"Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis","volume":"80","author":"S\u00f6rensen","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.06.004_bib42","doi-asserted-by":"crossref","first-page":"F471","DOI":"10.1152\/ajprenal.00189.2014","article-title":"Pharmacological and genetic depletion of fibrinogen protects from kidney\u00a0fibrosis","volume":"307","author":"Craciun","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2017.06.004_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12014-015-9092-7","article-title":"Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria","volume":"12","author":"\u00d8vrehus","year":"2015","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.ekir.2017.06.004_bib44","doi-asserted-by":"crossref","unstructured":"Zhang ZY, Ravassa S, Pejchinovski M, et\u00a0al. A urinary fragment of mucin-1 subunit a is a novel biomarker associated with renal dysfunction in the general population [e-pub ahead of print]. Kidney Int Rep. http:\/\/dx.doi.org\/10.1016\/j.ekir.2017.03.012. Accessed July 7, 2017.","DOI":"10.1016\/j.ekir.2017.03.012"},{"key":"10.1016\/j.ekir.2017.06.004_bib45","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2362.2012.02674.x","article-title":"Implementation of proteomic biomarkers: making it work","volume":"42","author":"Mischak","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ekir.2017.06.004_bib46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clinbiochem.2012.09.025","article-title":"Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience","volume":"46","author":"Mischak","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ekir.2017.06.004_bib47","doi-asserted-by":"crossref","first-page":"198ra106","DOI":"10.1126\/scitranslmed.3005807","article-title":"Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV)","volume":"5","author":"Klein","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2017.06.004_bib48","first-page":"1","article-title":"Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease\u00a0progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion","author":"Critselis","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917301651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917301651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T17:21:01Z","timestamp":1535736061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917301651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2468024917301651"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.06.004","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}